Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. (PELVICATHLE)

7 de septiembre de 2026 actualizado por: Centre Hospitalier Universitaire de Saint Etienne

Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. Single-Center Randomized Controlled Stepped-Wedge Trial

A prevalence of urinary incontinence ranging from 5.7% to 80% has been observed in young nulliparous athletes during their activity.

The usual recommendations for managing adult women do not seem to be transferable.

Young nulliparous athletes need specific educational and behavioral interventions and an alternative to pelvic floor muscle strengthening.

A multimodal and multidimensional intervention for athletes and coaches combining specific pelvic health education and strengthening of lumbopelvic-abdominal stability appears to be an innovative and optimal solution for reducing the symptoms of urinary incontinence in young nulliparous women who participate in athletics.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

198

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

  • Francia
      • Saint-Etienne, Francia, 42055
        • CHU de Saint-Etienne
        • Investigador principal:
          • Pascal EDOUARD, PHD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria :

  • Female subject, nulliparous
  • Member of an athletics club affiliated with the French Athletics Federation (FFA)
  • At least 15 years old at the start of the study and belonging to the U16/U18/U20/U23 categories (born between January 1, 2005, and September 1, 2011)
  • Having internet access
  • Having access to a digital device (computer, tablet, mobile phone)
  • Affiliated with or covered by a social security scheme
  • Having freely given their express consent, as well as the express consent of both parents for minor participants

Exclusion Criteria :

  • Any individual deprived of their liberty or subject to legal protection (guardianship, curatorship, or protective supervision).
  • A pregnant woman, a woman who has been pregnant, or a woman planning a pregnancy within the last nine months.
  • Any individual unable to understand the purpose and conditions of the study.
  • Any individual unable to give their consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Control condition
Usual activities
Otro: Usual activities
Collection of data on routine activities
Experimental: Interventional condition
Combined pelvic health education and lumbar-pelvic-abdominal stability strengthening program.
Otro: Combined pelvic health education and lumbar-pelvic-abdominal stability strengthening programme.

The intervention will consist of participants:

i) reviewing educational content (8 educational videos online)

ii) participating in two in-person sessions at the athletics club and performing lumbar-pelvic-abdominal stability exercises

iii) learning and implementing recommendations for empowering themselves in pelvic health management.

iv) complete reports in 6 questionnaires during follow-up.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Urinary incontinence symptoms
Periodo de tiempo: Week 1, 7, 13, 19, 25, 31
Severity of urinary incontinence symptoms as measured by the ICIQ-UI-SF score (International Consultation on Incontinence Questionnaire - Short Form for Urinary Incontinence). Scores typically range from 0 to 21. The higher the score, the more severe the urinary incontinence.
Week 1, 7, 13, 19, 25, 31

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The program's effects on the prevalence of urinary incontinence
Periodo de tiempo: Week 1, 7, 13, 19, 25, 31
The program's effects on the prevalence of urinary incontinence will be measured using the ICIQ-UI-SF questionnaire, with a dichotomous interpretation of the score: 0 = continent, ≥1 = incontinent.
Week 1, 7, 13, 19, 25, 31
Effects of the intervention on athletes' knowledge of the pelvic-perineal region
Periodo de tiempo: Week 1, 31
A questionnaire we have developed will measure the effects of the intervention on athletes' knowledge of the pelvic and perineal region. It will consist of 10 questions. This outcome will be assessed by comparing the mean number of correct answers (on a scale of 0 to 10) within and between groups.
Week 1, 31
The program's effects on associated pelvic and perineal symptoms
Periodo de tiempo: Week 1, 31
The ODS-S questionnaires measure associated pelvic and perineal symptoms. This criterion will be assessed by comparing the mean total scores (on a scale of 0 to 20) within and between groups.
Week 1, 31
The program's effects on urinary dysfunction.
Periodo de tiempo: Week 1, 31
Section C of the LURN-SI29 questionnaire, which assesses urinary dysfunction. This criterion will be evaluated by comparing the mean total scores (on a scale of 0 to 20) within and between groups.
Week 1, 31
Number of educational contents viewed
Periodo de tiempo: Week 13, 19, 25
Measured by tracking content views at the end of the session.
Week 13, 19, 25
Practicing lower back, pelvic, and abdominal stability exercises
Periodo de tiempo: Week 1, 7, 13, 19, 25, 31
Measured by collecting the frequency of implementation.
Week 1, 7, 13, 19, 25, 31
The dose-response effect related to adherence
Periodo de tiempo: Week 1, 7, 13, 19, 25, 31
Assessed by measuring the effects on the ICIQ-UI-SF score based on the frequency of exercise implementation. Scores typically range from 0 to 21. The higher the score, the more severe the urinary incontinence.
Week 1, 7, 13, 19, 25, 31
Program satisfaction
Periodo de tiempo: Week 31
Assessed using a questionnaire. This criterion will be expressed as the average of the total scores for the satisfaction and recommendation questions (on a scale of 0 to 10). A score of "10" indicates high satisfaction and a strong recommendation.
Week 31
Trends in Top Athletic Performance
Periodo de tiempo: Week 1, 7, 13, 19, 25, 31

Measured by the best performance (time/distance) in the most common track and field event.

Time is measured in seconds and minutes. Distance is measured in meters.
Week 1, 7, 13, 19, 25, 31
Number of educational contents viewed by coaches
Periodo de tiempo: Week 13, 19, 25
Measured by tracking content views at the end of the session
Week 13, 19, 25
Coaches' level of knowledge regarding the pelvic-perineal region
Periodo de tiempo: Week 1, 31
Assessed using a 10-question questionnaire. This criterion will be expressed through an intra-group and inter-group comparison of the average number of correct answers (on a scale of 0 to 10).
Week 1, 31
Practicing lumbar-pelvic-abdominal stability exercises
Periodo de tiempo: Week 1, 7, 13, 19, 25, 31
Measured by collecting the frequency as specified in a questionnaire
Week 1, 7, 13, 19, 25, 31
Coaches' satisfaction with the program
Periodo de tiempo: Week 31
Assessed using a questionnaire. This criterion will be expressed as the average of the total scores for the satisfaction and recommendation questions (on a scale of 0 to 10). A score of "10" indicates high satisfaction and a strong recommendation.
Week 31

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Centre Hospitalier Universitaire de Saint Etienne

Investigadores

  • Investigador principal: Pascal EDOUARD, PHD, CHU de Saint-Etienne

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de septiembre de 2026

Finalización primaria (Estimado)

1 de junio de 2027

Finalización del estudio (Estimado)

1 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

2 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

8 de junio de 2026

Publicado por primera vez (Actual)

12 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

7 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 26CH163
  • ANSM (Otro identificador: 2024-A02435-42)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir